Intelligent Bio Solutions

Intelligent Bio Solutions Equity

The The Equity of Intelligent Bio Solutions (INBS) as of Oct 23, 2026 is 5.51 M USD. In the previous year, The Equity was 3.00 M USD — a change of 83.93% (higher).

Equity

5.51 MUSD

YoY

83.93%

Last updated:

In 2026, Intelligent Bio Solutions's equity was 5.51 M USD, a 83.93% increase from the 3.00 M USD equity in the previous year.

The Intelligent Bio Solutions Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
-4.62 M USD
Jan 1, 2020
-5.19 M USD
Jan 1, 2021
15.06 M USD
Jan 1, 2022
6.55 M USD
Jan 1, 2023
3.80 M USD
Jan 1, 2024
8.33 M USD
Jan 1, 2025
3.00 M USD
Jan 1, 2026
5.51 M USD
The Intelligent Bio Solutions Equity history
YEAREquityYoY
5.51 MUSD+83.93%
3.00 MUSD-64.03%
8.33 MUSD+119.25%
3.80 MUSD-41.96%
6.55 MUSD-56.53%
15.06 MUSD-390.33%
-5.19 MUSD+12.38%
-4.62 MUSD+5.48%
-4.38 MUSD-26.00%
-5.91 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Intelligent Bio Solutions Stock analysis

What does Intelligent Bio Solutions do? Intelligent Bio Solutions, Inc. generates revenue through its Commercially available Intelligent Fingerprinting Products (IFPG) segment, which includes a portable drug screening system analyzing fingerprint sweat via a one-time cartridge and handheld reader. The company also develops diagnostic tests under the Development Stage Saliva Glucose Biosensor Platform (SGBP), targeting diabetic patients with a non-invasive saliva glucose biosensor (SGB) intended to replace finger-prick blood monitoring. Its biosensor platform supports multiple biological analyte detection for point-of-care diagnostic tests (POCT) in clinical chemistry, immunology, tumor markers, allergens, and endocrinology. The firm serves primary health practitioners and patients seeking non-invasive monitoring solutions. The company's product portfolio features the IFPG segment's portable drug screening system, which is sold to healthcare providers and law enforcement agencies for rapid drug testing. The SGBP segment focuses on developing the Saliva Glucose Biosensor (SGB), a point-of-care diagnostic test expected to address the needs of diabetic patients requiring frequent glucose monitoring without invasive procedures. The biosensor platform enables detection of multiple analytes, expanding the company's offerings in clinical chemistry and related diagnostic fields. Intelligent Bio Solutions, Inc. targets primary health practitioners and patients as key segments for its non-invasive diagnostic solutions. The IFPG segment's portable drug screening system is designed for use in clinical and law enforcement settings, while the SGBP segment's Saliva Glucose Biosensor aims to provide a convenient alternative to traditional blood glucose monitoring for diabetic patients. The company's development stage products focus on replacing invasive methods with real-time, non-invasive monitoring technologies. Intelligent Bio Solutions is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Intelligent Bio Solutions's Equity

Intelligent Bio Solutions's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Intelligent Bio Solutions's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Intelligent Bio Solutions's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Intelligent Bio Solutions's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Intelligent Bio Solutions’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Intelligent Bio Solutions stock

The Equity of Intelligent Bio Solutions is 5.51 M USD in 2026.

The Equity of Intelligent Bio Solutions changed from 3.00 M USD to 5.51 M USD, representing a 83.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Intelligent Bio Solutions since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Intelligent Bio Solutions historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Intelligent Bio Solutions

All Key Metrics — Intelligent Bio Solutions